Tearsheet

Axsome Therapeutics (AXSM)

Market Price (9/16/2025): $117.79 | Market Cap: $5.8 Bil
Sector: Health Care | Industry: Biotechnology

Axsome Therapeutics (AXSM)

Market Price (9/16/2025): $117.79
Market Cap: $5.8 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 70%	Weak multi-year price returns 2Y Excs Rtn is -2.5%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -208 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -42%
1	Low stock price volatility Vol 12M is 46%		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -24%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.8%

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 70%
1	Low stock price volatility Vol 12M is 46%
2	Weak multi-year price returns 2Y Excs Rtn is -2.5%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -208 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -42%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -24%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.8%

Market Valuation

	9/16/25	2024	2023	2022	2021
Share Price CYE	$117.79	$84.61	$79.59	$77.13	$37.78
Market Cap CYE ($ Bil)	5.8	4.1	3.8	3.4	1.4
Total Debt ($ Bil)	0.2	0.2	0.2	0.1	0.0
Total Cash ($ Bil)	0.3	0.3	0.4	0.2	0.1
Enterprise Value ($ Bil)	5.7	4.3	4.0	3.5	1.4
Valuation Ratios
P/S TTM	11.8	10.5	13.4	62.7	0.0
P/EBIT TTM	-24.3	-14.4	-15.6	-17.4	-11.4
P/E TTM	-23.6	-14.1	-15.1	-16.8	-10.9
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.9
P/E TTM (Sector)	-1.9	-1.6	-1.5	-1.4	-2.9

	9/16/25	2024	2023
Share Price CYE	$117.79	$84.61	$79.59
Market Cap CYE ($ Bil)	5.8	4.1	3.8
Total Debt ($ Bil)	0.2	0.2	0.2
Total Cash ($ Bil)	0.3	0.3	0.4
Enterprise Value ($ Bil)	5.7	4.3	4.0
Valuation Ratios
P/S TTM	11.8	10.5	13.4
P/EBIT TTM	-24.3	-14.4	-15.6
P/E TTM	-23.6	-14.1	-15.1
Sector Ratios
P/S TTM (Sector)	3.8	3.6	4.1
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-1.9	-1.6	-1.5

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
AXSM Return	-21%	-54%	104%	3%	6%	38%	15%
Peers Return	9%	5%	5%	5%	-7%	17%	37%
S&P 500 Return	16%	27%	-19%	24%	23%	12%	104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACT, PRGO, PCRX, ABBV, AMGN. See AXSM Returns vs. Peers.
[3] 2025 data is for the year up to 9/15/2025 (YTD)

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Axsome Therapeutics Earnings Notes
2	How Does AXSM Stack Up Against Its Peers?	Peer Comparison
3	AXSM Dip Buy Analysis
4	Axsome Therapeutics (AXSM) Operating Cash Flow Comparison	Financials
5	Axsome Therapeutics (AXSM) Net Income Comparison	Financials
6	Axsome Therapeutics (AXSM) Operating Income Comparison	Financials
7	Axsome Therapeutics (AXSM) Revenue Comparison	Financials
8	Axsome Therapeutics Market Price	Market Price
9	Axsome Therapeutics vs. S&P500 Correlation	Correlation
10	Axsome Therapeutics Price Volatility	Volatility
11	ARTICLES
12	What’s Happening With Axsome Therapeutics Stock?		October 14th, 2021
13	Axsome Therapeutics Stock Rises 36% In A Month But Will The Rally Continue?		September 17th, 2021
14	Will Axsome Stock Rebound After A 19% Fall In A Month?		July 22nd, 2021
15	What’s Next For Axsome Therapeutics Stock After A 13% Rise In A Month?		June 18th, 2021

	Title
0	DASHBOARDS
1	What’s Happening With Axsome Therapeutics Stock?
2	Axsome Therapeutics Stock Rises 36% In A Month But Will The Rally Continue?
3	Will Axsome Stock Rebound After A 19% Fall In A Month?
4	What’s Next For Axsome Therapeutics Stock After A 13% Rise In A Month?
5	ARTICLES
6	Axsome Therapeutics Earnings Notes
7	How Does AXSM Stack Up Against Its Peers?
8	AXSM Dip Buy Analysis
9	Axsome Therapeutics (AXSM) Operating Cash Flow Comparison
10	Axsome Therapeutics (AXSM) Net Income Comparison
11	Axsome Therapeutics (AXSM) Operating Income Comparison
12	Axsome Therapeutics (AXSM) Revenue Comparison
13	Axsome Therapeutics Market Price
14	Axsome Therapeutics vs. S&P500 Correlation
15	Axsome Therapeutics Price Volatility

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	NXTT	Next Technology	18947.6%	1080.3%
2	VCIG	VCI Global	2528.6%	-66.8%
3	BDSX	Biodesix	1926.1%	-75.2%
4	CLSD	Clearside Biomedical	1136.3%	-72.3%
5	SDOT	Sadot	1033.9%	-78.2%
6	CHEK	Check-Cap	184.2%	114.2%
7	ATCH	AtlasClear	153.8%	-89.7%
8	HSDT	Helius Medical Technologies	141.7%	-96.4%
9	MTVA	MetaVia	115.5%	-26.1%
10	IHT	InnSuites Hospitality Trust	66.0%	54.9%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ATYR	aTyr Pharma	-83.2%	-72.0%
2	NAKA	Kindly MD	-55.4%
3	REX	REX American Resources	-49.8%	-26.7%
4	FAAS	DigiAsia	-39.2%	-83.2%
5	EVTV	Envirotech Vehicles	-32.8%	-77.4%
6	WLDS	Wearable Devices	-30.0%	-24.4%
7	ZONE	CleanCore Solutions	-29.5%	107.8%
8	CGTX	Cognition Therapeutics	-29.0%	119.6%
9	SIDU	Sidus Space	-28.7%	-80.8%
10	BNGO	Bionano Genomics	-28.6%	-84.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	NXTT	Next Technology	18985.5%	1080.3%
2	BDSX	Biodesix	1658.4%	-75.2%
3	VCIG	VCI Global	1460.0%	-66.8%
4	CLSD	Clearside Biomedical	1075.2%	-72.3%
5	SDOT	Sadot	806.7%	-78.2%
6	WLDS	Wearable Devices	539.8%	-24.4%
7	QMMM	QMMM	536.6%	5505.5%
8	ATCH	AtlasClear	382.9%	-89.7%
9	OPI	Office Properties Income Trust	274.5%	-8.3%
10	CWD	CaliberCos	246.5%	-46.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	DGNX	Diginex	-83.7%
2	ATYR	aTyr Pharma	-81.4%	-72.0%
3	LGCL	Lucas GC	-73.2%	-78.3%
4	NAKA	Kindly MD	-72.8%
5	OCTO	Eightco	-67.8%	562.1%
6	YYGH	YY	-67.0%	-78.2%
7	SNTG	Sentage	-58.1%	57.5%
8	REX	REX American Resources	-50.7%	-26.7%
9	BINI	Bollinger Innovations	-49.2%	-100.0%
10	SLXN	Silexion Therapeutics	-49.2%	-88.0%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	11963.5%	11963.5%
2	GIBO	GIBO	7309.3%
3	CHSN	Chanson International	5551.3%	-99.3%
4	LNZA	LanzaTech Global	5145.9%	-85.7%
5	QMMM	QMMM	2490.3%	5505.5%
6	NXTT	Next Technology	2167.7%	1080.3%
7	VTAK	Catheter Precision	1543.9%	-70.5%
8	CURX	Curanex Pharmaceuticals	1282.0%	1282.0%
9	VCIG	VCI Global	1278.3%	-66.8%
10	OCTO	Eightco	800.6%	562.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	CJET	Chijet Motor	-93.3%	-95.1%
2	ELPW	Elong Power	-92.4%	-76.5%
3	STFS	Star Fashion Culture	-92.1%	-97.9%
4	ETS	Elite Express	-92.0%	-92.0%
5	NAKA	Kindly MD	-91.7%
6	BINI	Bollinger Innovations	-90.5%	-100.0%
7	FLYE	Fly-E	-89.8%	-81.2%
8	JEM	707 Cayman	-89.8%	-98.3%
9	NUTR	NusaTrip	-86.7%	-86.7%
10	CUPR	Cuprina	-84.9%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	NXTT	Next Technology	18947.6%	1080.3%
2	VCIG	VCI Global	2528.6%	-66.8%
3	BDSX	Biodesix	1926.1%	-75.2%
4	CLSD	Clearside Biomedical	1136.3%	-72.3%
5	SDOT	Sadot	1033.9%	-78.2%
6	CHEK	Check-Cap	184.2%	114.2%
7	ATCH	AtlasClear	153.8%	-89.7%
8	HSDT	Helius Medical Technologies	141.7%	-96.4%
9	MTVA	MetaVia	115.5%	-26.1%
10	IHT	InnSuites Hospitality Trust	66.0%	54.9%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ATYR	aTyr Pharma	-83.2%	-72.0%
2	NAKA	Kindly MD	-55.4%
3	REX	REX American Resources	-49.8%	-26.7%
4	FAAS	DigiAsia	-39.2%	-83.2%
5	EVTV	Envirotech Vehicles	-32.8%	-77.4%
6	WLDS	Wearable Devices	-30.0%	-24.4%
7	ZONE	CleanCore Solutions	-29.5%	107.8%
8	CGTX	Cognition Therapeutics	-29.0%	119.6%
9	SIDU	Sidus Space	-28.7%	-80.8%
10	BNGO	Bionano Genomics	-28.6%	-84.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	NXTT	Next Technology	18985.5%	1080.3%
2	BDSX	Biodesix	1658.4%	-75.2%
3	VCIG	VCI Global	1460.0%	-66.8%
4	CLSD	Clearside Biomedical	1075.2%	-72.3%
5	SDOT	Sadot	806.7%	-78.2%
6	WLDS	Wearable Devices	539.8%	-24.4%
7	QMMM	QMMM	536.6%	5505.5%
8	ATCH	AtlasClear	382.9%	-89.7%
9	OPI	Office Properties Income Trust	274.5%	-8.3%
10	CWD	CaliberCos	246.5%	-46.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	DGNX	Diginex	-83.7%
2	ATYR	aTyr Pharma	-81.4%	-72.0%
3	LGCL	Lucas GC	-73.2%	-78.3%
4	NAKA	Kindly MD	-72.8%
5	OCTO	Eightco	-67.8%	562.1%
6	YYGH	YY	-67.0%	-78.2%
7	SNTG	Sentage	-58.1%	57.5%
8	REX	REX American Resources	-50.7%	-26.7%
9	BINI	Bollinger Innovations	-49.2%	-100.0%
10	SLXN	Silexion Therapeutics	-49.2%	-88.0%

Peer Comparisons for Axsome Therapeutics

Financials

	AXSM	ACT	PRGO	PCRX	ABBV	AMGN	Median
Name	Axsome T.	Enact	Perrigo	Pacira B.	AbbVie	Amgen
Mkt Price	116.78	38.22	21.75	26.86	217.61	274.40	77.50
Mkt Cap	5.8	5.7	3.0	1.2	384.7	147.6	5.8
Rev LTM	495	1,226	4,326	706	58,328	34,917	2,776
Op Inc LTM	-208	-	413	69	13,695	8,192	413
FCF LTM	-121	701	257	117	18,239	10,605	479
FCF 3Y Avg	-134	641	238	143	20,273	8,590	439
CFO LTM	-121	701	366	135	19,283	12,013	533
CFO 3Y Avg	-133	641	342	159	21,154	9,753	491

Growth & Margins

	AXSM	ACT	PRGO	PCRX	ABBV	AMGN	Median
Name	Axsome T.	Enact	Perrigo	Pacira B.	AbbVie	Amgen
Rev Chg LTM	69.8%	3.4%	-2.3%	2.3%	6.1%	12.9%	4.7%
Rev Chg 3Y Avg	699.5%	3.7%	-0.0%	4.8%	0.6%	10.0%	4.3%
Rev Chg Q	72.1%	1.9%	-0.9%	1.7%	6.6%	9.4%	4.3%
QoQ Delta Rev Chg LTM	14.5%	0.5%	-0.2%	0.4%	1.7%	2.3%	1.1%
Op Mgn LTM	-42.0%	-	9.6%	9.7%	23.5%	23.5%	9.7%
Op Mgn 3Y Avg	-73.9%	-	6.2%	11.5%	27.2%	26.4%	11.5%
QoQ Delta Op Mgn LTM	13.3%	-	0.3%	-3.2%	1.0%	1.6%	1.0%
CFO/Rev LTM	-24.4%	57.1%	8.5%	19.1%	33.1%	34.4%	26.1%
CFO/Rev 3Y Avg	-47.6%	54.5%	7.7%	23.1%	37.5%	32.0%	27.5%
FCF/Rev LTM	-24.5%	57.1%	5.9%	16.6%	31.3%	30.4%	23.5%
FCF/Rev 3Y Avg	-47.8%	54.5%	5.3%	20.8%	36.0%	28.2%	24.5%

Valuation

	AXSM	ACT	PRGO	PCRX	ABBV	AMGN	Median
Name	Axsome T.	Enact	Perrigo	Pacira B.	AbbVie	Amgen
Mkt Cap	5.8	5.7	3.0	1.2	384.7	147.6	5.8
P/S	11.7	4.7	0.7	1.7	6.6	4.2	4.5
P/EBIT	-24.1	6.3	10.6	-13.4	65.3	14.2	8.5
P/E	-23.4	8.5	-37.4	-9.6	102.2	22.3	-0.6
P/CFO	-47.9	8.2	8.2	9.1	20.0	12.3	8.6
Total Yield	-4.3%	13.9%	-1.4%	-10.4%	3.9%	7.9%	1.3%
Dividend Yield	0.0%	2.0%	1.3%	0.0%	2.9%	3.4%	1.6%
FCF Yield 3Y Avg	-3.4%	13.4%	6.1%	10.5%	7.3%	6.2%	6.7%
D/E	0.0	0.1	1.2	0.5	0.2	0.4	0.3
Net D/E	-0.0	-0.3	1.1	0.2	0.2	0.3	0.2

Returns

	AXSM	ACT	PRGO	PCRX	ABBV	AMGN	Median
Name	Axsome T.	Enact	Perrigo	Pacira B.	AbbVie	Amgen
1M Rtn	6.9%	2.1%	-3.0%	8.4%	5.3%	-7.4%	3.7%
3M Rtn	14.8%	7.2%	-17.5%	10.4%	15.0%	-6.4%	8.8%
6M Rtn	-7.1%	15.6%	-21.3%	15.2%	3.3%	-12.0%	-1.9%
12M Rtn	24.7%	8.3%	-18.2%	104.9%	16.1%	-14.7%	12.2%
3Y Rtn	97.3%	89.9%	-39.3%	-49.9%	69.1%	30.6%	49.9%
1M Excs Rtn	5.1%	-2.3%	-6.7%	5.2%	4.0%	-7.0%	0.9%
3M Excs Rtn	1.5%	-2.8%	-28.1%	0.1%	4.2%	-17.0%	-1.4%
6M Excs Rtn	-21.5%	-1.6%	-35.7%	0.1%	-12.7%	-28.4%	-17.1%
12M Excs Rtn	9.2%	-7.8%	-34.2%	87.5%	-3.3%	-33.2%	-5.6%
3Y Excs Rtn	25.7%	12.0%	-102.0%	-116.8%	8.2%	-42.1%	-16.9%

Comparison Analyses

	Title
0	How Does AXSM Stack Up Against Its Peers?

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		2/18/2025	2/23/2024	2/28/2023	3/1/2022	3/1/2021	3/12/2020
Key Financials
Total Revenue	495	386	271	50	0	0	0
Ebitda	-231	-273	-225	-175	-125	-100	-67
Operating Income	-208	-252	-183	-177	-125	-99	-67
Net Income	-247	-287	-239	-187	-130	-103	-68
EPS	-5.07	-5.99	-5.27	-4.60	-3.47	-2.77	-2.01
Growth Rates
Total Revenue Growth	69.8%	42.5%	440.8%	∞%	-	-	-
EBITDA Growth	22.7%	-21.2%	-28.3%	-40.7%	-24.3%	-49.5%	-125.1%
Operating Income Growth	20.5%	-38.0%	-3.6%	-41.5%	-25.9%	-47.7%	-105.7%
Net Income Growth	20.0%	-20.1%	-27.8%	-43.5%	-26.7%	-50.6%	-120.7%
Margins
EBITDA Margin	-46.6%	-70.7%	-83.1%	-350.5%	-	-	-
Operating Income Margin	-42.0%	-65.5%	-67.6%	-352.7%	-	-	-
Net Income Margin	-49.9%	-74.5%	-88.4%	-374.0%	-	-	-
Cash & Debt
Total Cash	303	315	386	201	86	184	220
Total Debt	217	193	186	95	50	50	20
Net Debt / (Cash)	-86	-122	-200	-106	-37	-134	-200
Cash Flows
Net Cash from Operations	-121	-128	-145	-117	-108	-78	-46
Free Cash from Operations	-121	-129	-146	-117	-109	-79	-46
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/4/2025	5/5/2025	2/18/2025	11/12/2024	8/5/2024	5/6/2024	2/23/2024	11/6/2023	8/7/2023	5/9/2023	2/28/2023	11/7/2022
Key Financials Quarterly
Total Revenue	150	121	119	105	87	75	72	58	47	95	24	17
Ebitda	-45	-55	-71	-61	-76	-65	-97	-60	-63	-5	-58	-41
Operating Income	-45	-55	-62	-46	-76	-69	-55	-62	-59	-7	-56	-42
Net Income	-48	-59	-75	-65	-79	-68	-99	-62	-67	-11	-61	-45
EPS	-0.97	-1.22	-1.54	-1.34	-1.67	-1.44	-2.08	-1.32	-1.54	-0.26	-1.41	-1.07
Key Financials TTM
Total Revenue TTM	495	432	386	338	291	251	271	223	182	145	50	26
Ebitda TTM	-231	-262	-273	-299	-298	-286	-225	-187	-167	-142	-175	-150
Operating Income TTM	-208	-239	-252	-246	-262	-245	-183	-184	-164	-145	-177	-153
Net Income TTM	-247	-278	-287	-311	-309	-296	-239	-202	-184	-159	-187	-160
Growth Rates Quarterly
Total Revenue Growth	72.1%	62.0%	66.0%	81.3%	86.7%	-20.7%	193.5%	243.1%	429.5%	-	-	-
EBITDA Growth	41.0%	16.2%	26.9%	-0.3%	-20.0%	-1288.9%	-65.8%	-48.2%	-65.6%	87.6%	-78.6%	-23.0%
Operating Income Growth	40.9%	19.2%	-11.9%	25.8%	-28.6%	-950.9%	1.2%	-46.7%	-47.4%	82.9%	-70.9%	-27.1%
Net Income Growth	39.5%	13.1%	24.1%	-3.9%	-18.1%	-509.4%	-61.1%	-38.8%	-62.1%	71.7%	-80.2%	-28.5%
Margins Quarterly
EBITDA Margin	-29.9%	-45.2%	-59.4%	-57.8%	-87.3%	-87.3%	-135.0%	-104.5%	-135.7%	-5.0%	-238.9%	-241.8%
Operating Income Margin	-29.9%	-45.7%	-51.9%	-44.1%	-87.1%	-91.6%	-77.0%	-107.8%	-126.3%	-6.9%	-228.6%	-252.0%
Net Income Margin	-32.0%	-48.9%	-63.1%	-61.7%	-91.0%	-91.1%	-137.9%	-107.6%	-143.8%	-11.9%	-251.3%	-266.1%
Cash & Debt
Total Cash	303	301	315	327	316	331	386	417	437	247	201	228
Total Debt	217	211	193	192	192	189	186	186	185	148	95	94
Net Debt / (Cash)	-86	-90	-122	-135	-124	-142	-200	-231	-252	-99	-106	-133
Cash Flows Quarterly
FCF from Operations	-32	-43	-26	-19	-30	-53	-30	-54	-55	-6	-28	-23
Cash Flows TTM
FCF from Operations TTM	-121	-118	-128	-133	-167	-193	-145	-142	-111	-90	-117	-118
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-14.4%	-19.4%	-23.3%	-18.4%	-31.5%	-30.3%	-26.6%	-31.8%	-33.4%	-4.2%	-37.2%	-30.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-17.0%	-20.9%	-23.9%	-24.4%	-27.1%	-26.9%	-22.1%	-23.7%	-23.4%	-23.3%	-29.4%	-27.4%

Segment Financials

Revenue by Segment

$ Mil	2024	2023
Auvelity	130	5
Sunosi	72	45
Sunosi license revenue	66	0
Sunosi royalty revenue	2	0
Total	271	50

Assets by Segment

$ Mil	2024	2023	2022	2021	2020
Business of developing and delivering novel therapies for the management of CNS disorders			88	186	221
Total			88	186	221

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$116.78
Market Cap ($ Bil)	5.8
First Trading Date	11/19/2015
Distance from 52W High	-15.2%
	50 Days	200 Days
DMA Price	$112.11	$108.27
DMA Trend	up	up
Distance from DMA	4.2%	7.9%
	3M	1YR
Volatility	34.2%	46.3%
Downside Capture	24.20	63.82
Upside Capture	87.28	74.78
Correlation (SPY)	20.5%	29.9%

AXSM Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.70	1.02	0.96	0.64	0.69	0.66
Up Beta	0.70	2.11	1.88	0.51	0.54	0.45
Down Beta	0.11	0.04	0.28	1.03	0.93	0.78
Up Capture	204%	138%	96%	35%	68%	53%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	14	25	35	65	118	372
Down Capture	-88%	-24%	42%	64%	65%	91%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	7	16	27	60	128	375

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8292025
Short Interest: Shares Quantity	3,509,493
Short Interest: % Change Since 8152025	-5.7%
Average Daily Volume	576,553
Days-to-Cover Short Interest	6.09
Basic Shares Quantity	49,442,001
Short % of Basic Shares	7.1%

Returns Analyses

	Title
0	Axsome Therapeutics Stock Return Comparison

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/4/2025	3.4%	1.7%	19.9%
5/5/2025	3.8%	-4.0%	-1.9%
2/18/2025	-2.3%	-0.3%	-4.9%
11/12/2024	9.4%	1.6%	7.4%
8/5/2024	-1.4%	-1.6%	6.2%
5/6/2024	1.5%	-3.1%	-3.4%
2/20/2024	-12.6%	-11.3%	-17.2%
11/6/2023	-4.2%	-11.9%	5.3%
...
SUMMARY STATS
# Positive	13	11	12
# Negative	9	11	10
Median Positive	4.8%	3.4%	15.6%
Median Negative	-4.2%	-3.5%	-12.9%
Max Positive	10.2%	8.4%	76.4%
Max Negative	-46.5%	-55.3%	-48.1%

	Forward Returns
8/4/2025	3.4%	1.7%	19.9%
5/5/2025	3.8%	-4.0%	-1.9%
2/18/2025	-2.3%	-0.3%	-4.9%
11/12/2024	9.4%	1.6%	7.4%
8/5/2024	-1.4%	-1.6%	6.2%
5/6/2024	1.5%	-3.1%	-3.4%
2/20/2024	-12.6%	-11.3%	-17.2%
11/6/2023	-4.2%	-11.9%	5.3%
8/7/2023	2.0%	0.8%	14.7%
5/8/2023	5.4%	7.1%	1.5%
2/27/2023	5.0%	6.9%	4.7%
11/7/2022	-0.5%	3.4%	31.8%
3/1/2022	10.2%	2.6%	39.8%
11/8/2021	7.9%	-2.3%	-15.0%
8/9/2021	-46.5%	-55.3%	-48.1%
5/10/2021	4.9%	8.4%	16.7%
3/1/2021	2.7%	-3.5%	-15.0%
11/5/2020	-2.9%	4.1%	16.5%
8/10/2020	4.8%	1.2%	-10.9%
3/12/2020	-12.0%	-44.1%	-23.8%
11/7/2019	-9.7%	-0.2%	76.4%
8/8/2019	2.4%	6.9%	-0.5%
SUMMARY STATS
# Positive	13	11	12
# Negative	9	11	10
Median Positive	4.8%	3.4%	15.6%
Median Negative	-4.2%	-3.5%	-12.9%
Max Positive	10.2%	8.4%	76.4%
Max Negative	-46.5%	-55.3%	-48.1%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8042025	10-Q 6/30/2025
3312025	5052025	10-Q 3/31/2025
12312024	2182025	10-K 12/31/2024
9302024	11122024	10-Q 9/30/2024
6302024	8052024	10-Q 6/30/2024
3312024	5062024	10-Q 3/31/2024
12312023	2232024	10-K 12/31/2023
9302023	11062023	10-Q 9/30/2023
6302023	8072023	10-Q 6/30/2023
3312023	5092023	10-Q 3/31/2023
12312022	2282023	10-K 12/31/2022
9302022	11072022	10-Q 9/30/2022
6302022	8092022	10-Q 6/30/2022
3312022	5022022	10-Q 3/31/2022
12312021	3012022	10-K 12/31/2021
9302021	11082021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	JEFFS ROGER	8292025	Sell	122.30	20,000	2,446,000	13,572,120	Form
1	JEFFS ROGER	8262025	Sell	120.08	16,694	2,004,616	18,128,958	Form
2	Coleman Mark	5292025	Sell	105.47	3,750	395,512	5,314,317	Form
3	Coleman Mark	5202025	Sell	107.49	3,000	322,473	5,819,240	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Axsome Therapeutics (AXSM)

Market Price (9/16/2025): $117.79 | Market Cap: $5.8 BilSector: Health Care | Industry: Biotechnology

Axsome Therapeutics (AXSM)

Market Price (9/16/2025): $117.79Market Cap: $5.8 BilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Axsome Therapeutics (AXSM)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Axsome Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/16/2025): $117.79 | Market Cap: $5.8 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (9/16/2025): $117.79
Market Cap: $5.8 Bil
Sector: Health Care
Industry: Biotechnology